Eosinophilic Esophagitis

• EMA approval · 2026-04-20
  EMA Authorised: Dupixent (dupilumab) — Sanofi Winthrop Industrie

  The EMA authorised Dupixent (dupilumab) for multiple EU indications, including atopic dermatitis, prurigo nodularis, eosinophilic esophagiti…

• EMA approval · 2026-04-15
  EMA Authorised: Jorveza (Budesonide) — Dr. Falk Pharma GmbH

  EMA authorised Jorveza (budesonide) by Dr. Falk Pharma GmbH for eosinophilic esophagitis; the approval is designated orphan medicine with ac…

• FDA approval · 2024-09-12
  FDA Approved: DUPIXENT — Supplemental Application (sanofi-aventis U.S. LLC)

  FDA approved a supplemental application for Dupixent (dupilumab) submitted by sanofi-aventis U.S. LLC.

• FDA approval · 2024-01-25
  FDA Approved: DUPIXENT — Supplemental Application (sanofi-aventis U.S. LLC)

  FDA approved a supplemental application for Dupixent (dupilumab) filed by Sanofi‑Aventis U.S. LLC, indicating an approval of a supplement re…

• FDA approval · 2018-10-19
  FDA Approved: DUPIXENT — Supplemental Application (sanofi-aventis U.S. LLC)

  FDA approved a supplemental application for DUPIXENT (dupilumab) submitted by Sanofi-Aventis U.S. LLC.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.